Sign in

Bradford Seagraves

Research Analyst at North Bank Capital

Bradford Seagraves is the Founder and Chief Investment Officer at Northbank Capital Management, specializing in equity research and investment across diverse sectors with a notable focus on healthcare companies such as Nutex Health. He has experience engaging directly with company management during earnings calls and has previously held analyst and research roles at firms like Davenport and Bank of America Merrill Lynch. Seagraves launched Northbank Capital Management in 2021 and leverages over a decade of industry expertise. As a CFA charterholder, he is recognized for his rigorous investment analysis and commitment to professional excellence.

Bradford Seagraves's questions to Nutex Health (NUTX) leadership

Question · Q3 2025

Bradford Seagraves asked for an update on the share buyback program, Nutex Health's capital allocation priorities for its growing cash balance, and the current and projected inpatient utilization rates.

Answer

CFO Jon Bates confirmed that no shares have been bought back yet, as the program is being implemented. CEO Tom Vo and CFO Jon Bates outlined capital allocation priorities, including the share buyback, acquiring existing facilities, expanding the IPA business, and investing in current hospitals for service line enhancements like behavioral health. CEO Tom Vo reported current inpatient capacity at 25-30%, significantly up from two years ago, with a goal to increase it further over the next 12-24 months.

Ask follow-up questions

Fintool

Fintool can predict Nutex Health logo NUTX's earnings beat/miss a week before the call

Question · Q3 2025

Bradford Seagraves inquired about the status of the share buyback program, Nutex Health's capital allocation priorities for its growing cash balance, and the current and projected inpatient utilization rates across its hospitals.

Answer

CFO Jon Bates confirmed no shares have been bought back yet, as the program is being implemented. Both Jon Bates and CEO Tom Vo outlined capital allocation priorities, including the share buyback (with potential future increases), acquiring existing facilities, expanding the IPA business for symbiotic relationships, and investing in current hospitals to enhance service capabilities like behavioral health. Tom Vo stated inpatient utilization is currently 25-30% and has significantly increased over the past two years, with a strategic goal to further grow this capacity.

Ask follow-up questions

Fintool

Fintool can write a report on Nutex Health logo NUTX's next earnings in your company's style and formatting

Question · Q2 2025

Bradford Seagraves requested commentary on business performance and free cash flow trends quarter-to-date in Q3 and asked if the company planned to publish unaudited Q2 financial statements ahead of the full restated filing.

Answer

CFO John Bates indicated that the strong and consistent operational trends seen in the first half of 2025 have continued into Q3 but did not provide specific figures. He explained that while the company will consider providing more data, the immediate focus is on the restatement process, which primarily impacts non-cash items and does not change the business's strong fundamentals.

Ask follow-up questions

Fintool

Fintool can auto-update your Excel models when Nutex Health logo NUTX reports